Maxime Dely: What If One Technology Could Transform Patients’ Lives?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Sickle cell disease: What if one technology could transform patients’ lives?
Sickle cell disease is the most common genetic disorder in France, affecting 25,000 to 30,000 people. It remains a complex condition marked by severe pain, microvascular occlusions, strokes, necrosis, jaundice, and episodes of acute hemolytic anemia — all profoundly impacting daily life.
Despite ongoing prevention efforts, the disease continues to progress.
Yet one interventional treatment is truly reshaping patient care: automated red blood cell exchange.
Still underrecognized, this procedure — performed through apheresis systems — brings major benefits supported by numerous studies:
* Drastic reduction in acute crises by removing sickled red cells responsible for vascular occlusion.
* Significantly less iron overload compared with standard transfusion — a crucial long-term advantage.
* Faster procedure, enabling 2 to 3 times more red cell units to be exchanged in the same amount of time.
* More spaced-out sessions, greatly improving comfort and quality of life for patients.
Red blood cell exchange is not just an alternative — it is a major therapeutic advancement for a disease that remains insufficiently visible.
Promoting access to this therapy means offering patients safer, more effective, and more humane care.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
May 26, 2026, 11:36Abid Ur Rahman: Understanding the Coagulation Cascade and Hemostasis
-
May 26, 2026, 11:35Isaac Okello: The Real Sickle Cell Crisis Is Not Only the Disease Itself
-
May 26, 2026, 11:34Ziad Omar: PTT and aPTT Testing – Reading the Intristic Pathway of Coagulation
-
May 26, 2026, 11:33Megan Griffiths: Advancing the Understanding of Risk and Outcomes in Pulmonary Hypertension
-
May 26, 2026, 11:30Samantha Pasca: How Should We Manage Cardiovascular Disease in Patients With Hemophilia?
-
May 26, 2026, 11:05Hassan Raza։ When the Platelet Count Lies – Think Artifact Before Disease
-
May 26, 2026, 10:26Gestur Vidarsson: Could Antibody Fucosylation Help Predict FNAIT Severity
-
May 26, 2026, 10:17Alan Nurden: New Review Highlights the Importance of Mitochondria in Platelet Function
-
May 26, 2026, 10:12Zoe Cahill: Are We Designing Vascular Grafts for Structure Instead of Biology